Deutsche Bank AG Has $2.94 Million Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Deutsche Bank AG increased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 12.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 252,501 shares of the company's stock after purchasing an additional 27,282 shares during the quarter. Deutsche Bank AG owned 0.25% of Intellia Therapeutics worth $2,944,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of NTLA. ARK Investment Management LLC increased its position in shares of Intellia Therapeutics by 2.3% during the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock worth $146,174,000 after acquiring an additional 280,946 shares in the last quarter. Vanguard Group Inc. increased its holdings in Intellia Therapeutics by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock worth $118,816,000 after purchasing an additional 562,249 shares in the last quarter. Regeneron Pharmaceuticals Inc. acquired a new stake in Intellia Therapeutics in the 4th quarter valued at approximately $43,177,000. Geode Capital Management LLC raised its holdings in shares of Intellia Therapeutics by 2.0% in the fourth quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company's stock valued at $27,865,000 after purchasing an additional 45,930 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Intellia Therapeutics by 36.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,976,212 shares of the company's stock valued at $23,042,000 after buying an additional 528,962 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on NTLA. JPMorgan Chase & Co. restated a "neutral" rating and set a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Wolfe Research raised Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price target on the stock in a research report on Monday, April 21st. Citigroup cut their price objective on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Wedbush reissued a "neutral" rating and issued a $10.00 target price on shares of Intellia Therapeutics in a research note on Monday, May 19th. Finally, Morgan Stanley lowered shares of Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $36.90.

Intellia Therapeutics Stock Performance

Shares of NTLA stock traded up $0.16 on Tuesday, hitting $9.32. The company's stock had a trading volume of 3,690,793 shares, compared to its average volume of 2,573,158. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.18. The company has a market capitalization of $965.39 million, a PE ratio of -1.71 and a beta of 2.33. The stock's 50 day moving average is $7.99 and its 200-day moving average is $10.45.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. During the same period in the prior year, the firm earned ($1.12) EPS. The business's revenue for the quarter was down 42.6% on a year-over-year basis. On average, research analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.